Candel Therapeutics

CADL

Market cap $246M

NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will host a virtual Research and Development (R&D) Event from 11:00 am – 1:45 pm ET on Friday, December 5, 2025.

Candel Therapeutics Inc (NASDAQ:CADL) reported encouraging clinical progress across its cancer immunotherapy pipeline, along with the release of its third quarter 2025 financial results. The company recently presented new Phase 3 subgroup analyses of CAN-2409 in localized prostate cancer showing statistically significant improvement in disease-free survival and updated survival data from its Phase 1b CAN-3110 trial in recurrent high-grade glioma, underscoring the potential of its multimodal immunotherapies.

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival (DFS), independent of radiation therapy modality utilized                                                         Company plans to initiate pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) and progressive disease, despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026 Announced encouraging updated survival data for patients enrolled in its phase 1b clinical trial of CAN-3110 (linoserpaturev) in recurrent high-grade glioma (rHGG) Manuscript published in the scientific journal Science Translational Medicine, reporting the tissue response to CAN-3110 based on the analysis of serial tumor biopsies from two patients treated with multiple administrations of CAN-3110 in arm C of the phase 1b clinical trial Plan to submit a Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer in Q4 2026 Entered into a $130 million term loan facility with Trinity Capital Inc. for a $50 million drawn down at closing, with access to up to an additional $80 million Cash and cash equivalents of $87.0M, as of September 30, 2025, plus the upfront proceeds from the Trinity Capital debt facility, strengthens the Company's financial position to fund initiation of potentially registrational phase 3 trial of CAN-2409 in NSCLC and other planned operations into Q1 2027 NEEDHAM, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the third quarter ended September 30, 2025, and provided a corporate update.

Candel Therapeutics Inc (NASDAQ:CADL) will deliver three presentations at the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). “Candel's presentations at SITC 2025 exemplify our innovative approach to the discovery and development of novel immunotherapies,” said CEO Paul Peter Tak.

NEEDHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies to help patients fight cancer, today announced it will deliver three presentations at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, taking place November 5–9, 2025, in National Harbor, Maryland.

NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom.

Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr. Paul Peter Tak talked with Proactive about the company's recently secured $130 million term loan facility with Trinity Capital.

Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Dr Bali Pulendran, a leading authority in systems immunology and vaccinology, to its Research Advisory Board. Dr Pulendran is the Violetta L.

NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 for recurrent high-grade glioma.

Candel Therapeutics Inc (NASDAQ:CADL) said it has inked a five-year, $130 million term loan facility with Trinity Capital to strengthen its balance sheet and support late-stage development and potential commercialization of its cancer immunotherapies. The facility includes four tranches, with $50 million drawn at closing.